DS
SUPN icon

DRW Securities’s Supernus Pharmaceuticals SUPN Stock Holding History

DRW Securities’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,427
Closed -$392K – 1608
2025
Q2 		$392K Buy
+12,427
New +$398K 0.01% 603
2016
Q2 		– Sell
-29,965
Closed -$457K – 94
2016
Q1 		$457K Buy
+29,965
New +$391K 0.03% 52

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities's SUPN Position: Q3 2025 in Review

DRW Securities sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 12,427 shares — an estimated $392K sold.

DRW Securities first reported a position in SUPN in Q1 2016 and held it in 2 quarters. The position peaked at $457K in Q1 2016. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • DRW Securities reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • DRW Securities sold 12,427 Supernus Pharmaceuticals shares in Q3 2025, an estimated $392K.
  • DRW Securities first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • DRW Securities's Supernus Pharmaceuticals position peaked at $457K in Q1 2016.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.